Patents by Inventor Reinhard Wallich

Reinhard Wallich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Regulators of the Innate Immune System
    Publication number: 20110236455
    Abstract: The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H.
    Type: Application
    Filed: September 28, 2009
    Publication date: September 29, 2011
    Inventors: Peter Zipfel, Christina Skerka, Reinhard Wallich
  • REGULATORY PROTEIN PKE#83 FROM HUMAN KERATINOCYTES
    Publication number: 20070154911
    Abstract: The invention relates to an isolated polypeptide which is the same as or similar to (i.e., has the same function and effect as) a protein which occurs naturally in human keratinocytes and is more strongly expressed when the keratinocytes are in their activated state. The invention also relates to an isolated nucleic acid which codes a polypeptide or protein of this type that is typical for human keratinocytes and to the use of said polypeptide and said nucleic acid for detection, especially diagnostic purposes and/or for therapeutic purposes or the use of reagents, especially recombinant vector molecules and antibodies, against molecules of this type.
    Type: Application
    Filed: December 1, 2006
    Publication date: July 5, 2007
    Inventors: Michael Kramer, Michael Bechtel, Jeanette Reinartz, Birgit Schaefer, Reinhard Wallich
  • Medicament for treating a manifested lyme disease
    Patent number: 6761891
    Abstract: A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of B. burgdorferi, preferably an antibody which is specific for the 24 kDa antigen (OspC) of B. burgdorferi having the sequence shown in SEQ ID NO.2.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: July 13, 2004
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Markus M. Simon, Weimin Zhong, Reinhard Wallich, Michael D. Kramer
  • Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6676942
    Abstract: The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: January 13, 2004
    Assignees: SmithKline Beecham Biologicals (s.a.), Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Deutsches Krebs Forschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6113914
    Abstract: The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: September 5, 2000
    Assignee: Smithkline Beecham Biologicals (S.A.)
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 5942236
    Abstract: The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: August 24, 1999
    Assignees: SmithKline Beecham Biologicals, Max-Planck-Gesellschaft zur Forderung der Wissenschafter e.V., Duetsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer